JP2022543391A - トロフィネチドの組成物 - Google Patents

トロフィネチドの組成物 Download PDF

Info

Publication number
JP2022543391A
JP2022543391A JP2022506639A JP2022506639A JP2022543391A JP 2022543391 A JP2022543391 A JP 2022543391A JP 2022506639 A JP2022506639 A JP 2022506639A JP 2022506639 A JP2022506639 A JP 2022506639A JP 2022543391 A JP2022543391 A JP 2022543391A
Authority
JP
Japan
Prior art keywords
formula
compound
amount
pharmaceutically acceptable
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022506639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543391A5 (https=
JPWO2021026066A5 (https=
Inventor
クライヴ ブロワー，
マシュー ピーターソン，
ジェームズ マレー ショー，
ジェームズ アンソニー ボナー，
エティエンヌ デイヴィッド フランク フィリップ モニオット，
マーティン バーナード キャサリン ボウスマン，
セシリア ベッティ，
カレル ウィリー ルック デクロース，
ミムン アユブ，
Original Assignee
ニューレン ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューレン ファーマシューティカルズ リミテッド filed Critical ニューレン ファーマシューティカルズ リミテッド
Publication of JP2022543391A publication Critical patent/JP2022543391A/ja
Publication of JP2022543391A5 publication Critical patent/JP2022543391A5/ja
Publication of JPWO2021026066A5 publication Critical patent/JPWO2021026066A5/ja
Priority to JP2026003598A priority Critical patent/JP2026063085A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18—Carbon
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022506639A 2019-08-05 2020-08-03 トロフィネチドの組成物 Withdrawn JP2022543391A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026003598A JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882998P 2019-08-05 2019-08-05
US62/882,998 2019-08-05
PCT/US2020/044733 WO2021026066A1 (en) 2019-08-05 2020-08-03 Compositions of trofinetide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026003598A Division JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Publications (3)

Publication Number Publication Date
JP2022543391A true JP2022543391A (ja) 2022-10-12
JP2022543391A5 JP2022543391A5 (https=) 2023-08-15
JPWO2021026066A5 JPWO2021026066A5 (https=) 2023-08-15

Family

ID=74502416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506639A Withdrawn JP2022543391A (ja) 2019-08-05 2020-08-03 トロフィネチドの組成物
JP2026003598A Pending JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026003598A Pending JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Country Status (16)

Country Link
US (3) US11370755B2 (https=)
EP (1) EP4009962A4 (https=)
JP (2) JP2022543391A (https=)
KR (1) KR20220059479A (https=)
CN (1) CN114667136A (https=)
AU (1) AU2020324396B2 (https=)
BR (1) BR112022002229A2 (https=)
CA (1) CA3149633A1 (https=)
CL (1) CL2022000301A1 (https=)
CO (1) CO2022002616A2 (https=)
IL (1) IL290324A (https=)
JO (1) JOP20220027A1 (https=)
MX (1) MX2022001505A (https=)
MY (1) MY206115A (https=)
SA (1) SA522431585B1 (https=)
WO (1) WO2021026066A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220059479A (ko) 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물
MX2023014655A (es) * 2021-07-12 2024-01-12 Acadia Pharm Inc Formas cristalinas de trofinetida.
WO2025169163A1 (en) * 2024-02-10 2025-08-14 Teadus Pharma Private Limited Method for the synthesis of trofinetide and its analogues

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61155393A (ja) * 1984-11-23 1986-07-15 ソルベイ（ソシエテ　アノニム） アミノ酸からペプチドを合成する方法
JP2011503223A (ja) * 2007-11-19 2011-01-27 ソルヴェイ（ソシエテ アノニム） ペルシリル化ペプチドを製造する方法
JP2018138606A (ja) * 2011-01-27 2018-09-06 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
EP1888618A4 (en) * 2005-05-23 2009-07-15 Neuren Pharmaceuticals Ltd Analogs of glycyl-prolyl-glutamate
WO2007106555A2 (en) 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
KR20220059479A (ko) 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61155393A (ja) * 1984-11-23 1986-07-15 ソルベイ（ソシエテ　アノニム） アミノ酸からペプチドを合成する方法
JP2011503223A (ja) * 2007-11-19 2011-01-27 ソルヴェイ（ソシエテ アノニム） ペルシリル化ペプチドを製造する方法
JP2018138606A (ja) * 2011-01-27 2018-09-06 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療

Also Published As

Publication number Publication date
MY206115A (en) 2024-11-29
US12297172B2 (en) 2025-05-13
CA3149633A1 (en) 2021-02-11
EP4009962A1 (en) 2022-06-15
US11866406B2 (en) 2024-01-09
MX2022001505A (es) 2022-03-11
US20240109841A1 (en) 2024-04-04
KR20220059479A (ko) 2022-05-10
EP4009962A4 (en) 2023-08-09
CO2022002616A2 (es) 2022-06-10
US20220324799A1 (en) 2022-10-13
CL2022000301A1 (es) 2022-09-20
JP2026063085A (ja) 2026-04-10
BR112022002229A2 (pt) 2022-04-19
SA522431585B1 (ar) 2025-02-13
AU2020324396B2 (en) 2025-07-03
US20220055987A1 (en) 2022-02-24
AU2020324396A1 (en) 2022-03-10
IL290324A (en) 2022-04-01
JOP20220027A1 (ar) 2023-01-30
CN114667136A (zh) 2022-06-24
US11370755B2 (en) 2022-06-28
WO2021026066A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
JP7625531B2 (ja) 立体障害の大きなアミノ酸を含むペプチド化合物の製造方法
JP7430297B2 (ja) Ｎ－アルキルアミノ酸、およびｎ－アルキルアミノ酸を含むペプチドの製造方法
JP2026063085A (ja) トロフィネチドの組成物
AU2007327344B2 (en) Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl- D-tryptophan
CN102241739A (zh) 肽的生产和纯化方法
JP2015533156A (ja) 大環状デプシペプチドを製造するための液相プロセスおよび新規中間体
WO2015198505A1 (ja) 合成ペンタペプチドの製造法
CN115190882A (zh) 通过共同中间体有效制备多拉司他汀和奥里斯他汀类似物
TWI860373B (zh) 肽化合物的製造方法、保護基形成用試藥及縮合多環化合物
CN120476131A (zh) 涉及位阻三叔丁基色氨酸（Tbt）残基的肽合成方法
JP5807140B1 (ja) 合成ペンタペプチドの製造法
CN117916250A (zh) 空间位阻混合酸酐中间体参与的肽合成方法
EA049473B1 (ru) Композиции трофинетида
CN106459149A (zh) H‑inp‑(d)bal‑(d)trp‑phe‑apc‑nh2及其可药用盐的液相合成的方法
JP2002539132A (ja) ２０（ｓ）−カンプトテシンの糖−共役体の製造法
MXPA03000607A (es) Procedimiento quimico.
JP2000154198A (ja) 環状デプシペプチドの固相合成方法及びその中間体
US20250353810A1 (en) Process for the preparation of trofinetide
JP5982720B2 (ja) 高分子固体状支持体を用いたヒスチジル−プロリンアミド誘導体の製造方法
HK40096738A (zh) 包含n-取代氨基酸残基的环状化合物的制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230801

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230906

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260113

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260123